An official website of the United States government
Here’s how you know
Official websites use .gov A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Fact Sheet: HHS Details $5 Billion ‘Project NextGen’ Initiative to Stay Ahead of COVID-19
Thanks to the Biden-Harris Administration’s whole-of-government approach to combatting COVID-19, we are now in a better place in our response than at any point of the pandemic. However, we need to continue to support the development of a new generation of tools to stay ahead of COVID-19.
An initial investment of $5 billion, collectively referred to as Project NextGen, will accelerate and streamline the rapid development of the next generation of vaccines and treatments through public-private collaborations.
Based at the U.S. Department of Health and Human Services (HHS) and led by the Administration for Strategic Preparedness and Response (ASPR’s) Biomedical Advanced Research and Development Authority (BARDA) and the National Institutes of Health (NIH’s) National Institute of Allergy and Infectious Diseases (NIAID), Project NextGen will coordinate across the federal government and the private sector to advance the pipeline of new, innovative vaccines and therapeutics into clinical trials and potential review by the U.S. Food and Drug Administration (FDA) for authorization or approval, and commercial availability for the American people.
The program will focus on several areas, including:
Mucosal vaccines such as those delivered intranasally, which could have the potential to dramatically reduce infection and transmission, in addition to preventing serious illness and death.
Vaccines that provide broader protection against variants of concern and a longer duration of protection.
Pan-Coronavirus vaccines which would protect against several different coronaviruses.
New, and more durable monoclonal antibodies that are resilient against new variants as they arise.
Advancing new technologies that will improve access and enable faster, cheaper, rapid, and more flexible production of vaccines and therapeutics.
Announced on April 10, the program has already started the activities necessary to bring next generation vaccines and treatments to Americans, including but not limited to:
Advanced development efforts at BARDA to examine immune responses across vaccines, including furthering our understanding of what correlates of immunity can predict the success of next-generation vaccines.
Leveraging NIAID clinical trial networks to evaluate multiple early candidate vaccines.
Public-private partnerships between BARDA and vaccine and therapeutic developers to de-risk product development.
BARDA’s support of innovative manufacturing and platform approaches that will improve yields and will accelerate the availability of vaccines and therapeutics.
Building on experiences from HHS’s COVID-19 response efforts over the past 3-plus years, the Biden-Harris Administration will continue to address the ongoing threat of COVID-19 and to protect us against future epidemics from this same family of viruses.
View BARDA’s latest Request for Information (RFI), Areas of Interest under BARDA’s Broad Agency Announcement (BAA), and easy broad agency announcement (EZ-BAA) at:
For general media inquiries, please contact media@hhs.gov.
Content created by Assistant Secretary for Public Affairs (ASPA) Content last reviewed
Disclaimer Policy: Links with this icon () mean that you are leaving the HHS website.
The Department of Health and Human Services (HHS) cannot guarantee the accuracy of a non-federal website.
Linking to a non-federal website does not mean that HHS or its employees endorse the sponsors, information, or products presented on the website. HHS links outside of itself to provide you with further information.
You will be bound by the destination website's privacy policy and/or terms of service when you follow the link.
HHS is not responsible for Section 508 compliance (accessibility) on private websites.
For more information on HHS's web notification policies, see Website Disclaimers.